KEI Comments on NIH Prospective License To Chan Zuckerberg Biohub

On July 17, 2025, KEI submitted comments regarding the prospective Exclusive, Inter-Institutional Agreement-Institution Lead for the development and commercialization of engineered commensals to generate antigen-specific T and B cells (90 FR 29028), which is set to be given to CZ… Continue Reading

KEI Comments on NIH Exclusive License to Capstan for CAR T Autoimmune Treatment

On July 18, 2025, KEI submitted comments regarding the prospective exclusive licensing by the NIH of “The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases” (90 FR… Continue Reading

KEI Comments on NIH Exclusive License to Neurala for Central Nervous System Disorders

On June 2, 2025, Knowledge Ecology International (KEI) offered comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: c-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same”… Continue Reading

KEI Comments on NIH Exclusive License to Sangam Lifesciences for Drug Delivery Platform

On May 7, 2025, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” (90 FR 16878) to… Continue Reading

KEI Submissions to 2025 Special 301 Review

Annually, the Office of the United States Trade Representative spearheads the Special 301 review process, whose goal is to produce a report that names-and-shames countries that have committed perceived offenses against intellectual property rights. The USTR solicits written comments from… Continue Reading

The New NIH Intramural Research Program Access Planning Policy

Introduction In January 2025, the National Institutes of Health (NIH) introduced a new NIH Intramural Research Program Access Planning Policy (“IRP Access Planning Policy” or “Policy”). An NIH web page provides links to several documents describing the policy: https://osp.od.nih.gov/policies/innovation-and-translation#tab1/ The… Continue Reading

KEI Comments to the NIH on Cancer Treatment License to Straightline Bio

On December 26, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Anti-KK-LC-1 T Cell Receptors for the Treatment of Cancer” (89 FR 99888) to StraightLine… Continue Reading

KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment

On December 17, 2025, Knowledge Ecology International (KEI) provided comments to the National Institutes for Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Tumor Infiltrating Lymphocytes for the Treatment of Cancer” (89 FR 95224) to… Continue Reading

KEI Comments on NIH Exclusive License to Columbia for Ebola Technology

On December 5, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on the “Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Peptides and Peptide Microarrays for Detection and Differentiation of Antibody Responses to Ebola… Continue Reading

KEI Comments on NIH Exclusive License to Autala for Autoimmune Treatment

On September 3, 2024, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases” (89 FR 66730). The Federal Register notice… Continue Reading